UNSPSC 51294211: Reboxetine mesilate or mesylate

This classification denotes an antidepressant agent with the molecular formula C19H23NO3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L94J81YNNY, chemically known as (+/-)-(r*,s*)-2-((2-ethoxyphenoxy)phenylmethyl)morpholine methanesulfonate, but more generally known as reboxetine mesylate, which bears US NIH Compound Identifier 127150. European Medicines Agency schedules reboxetine mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15112MIG.

Most nations, for tariff purposes, schedule reboxetine mesylate under HS 29349990. As of Q4 2014, REBOXETINE MESYLATE remains US FDA's Preferred Term for this commodity. SMILES: CCOC1CCCCC1O[C@H](C2CCCCC2)[C@H]3CNCCO3.CS(=O)(=O)O.

UNSPSC 51294211 Reboxetine mesilate or mesylate is a Commodity code that in practice does not align with recent state and local procurement activity under this designation. The three recent opportunities tagged to the code involve naloxone and drug deactivation systems, a therapeutic pharmacy initiative addressing direct-to-manufacturer prescription relationships, and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing—none of which are reboxetine mesilate, a selective norepinephrine reuptake inhibitor antidepressant. The mismatch suggests either classification error in the source data or that the code is used as a placeholder for broader pharmaceutical procurement that does not match its nominal scope.

Issuing bodies soliciting under this code designation span county health departments, state HHS commissions, and multistate cooperative purchasing alliances. Seminole County, Florida posted an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly delivery to the Seminole County Community Health Building. The Texas Health and Human Services Commission issued an RFI in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026 with a March 26, 2026 deadline to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and maintain cGMP and DSCSA compliance. The code shows recent activity in Florida, Texas, and the Upper Midwest, but the actual pharmaceutical products being procured do not correspond to the code's stated drug name.